Prostate Volume and Benign Prostatic Hyperplasia Treatment

Clinical Significance Thresholds

A prostate volume greater than 30 cc is considered clinically significant when evaluating treatment options for benign prostatic hyperplasia (BPH), according to the American Urological Association 1
Prostates ≤30 grams are considered small and are appropriate for transurethral incision of the prostate (TUIP), as recommended by the European Association of Urology 2, 3
Prostates >30 cc qualify for treatment with 5-alpha reductase inhibitors (5-ARIs), which are only effective in demonstrably enlarged glands, as stated by the American Urological Association 1
Prostates >60 grams are considered large and may require simple prostatectomy (open, laparoscopic, or robotic-assisted) rather than transurethral approaches, according to the European Association of Urology 2, 3
A minimum prostate volume of >30 cc or PSA >1.5 ng/mL is necessary for reliable response to 5-ARI therapy, as recommended by the American Urological Association 1

Un volumen prostático >30 mL se considera clínicamente significativo al evaluar opciones de tratamiento para HPB, según la guía de Praxis Medical Insights 4
Los inhibidores de la 5-alfa reductasa (5-ARIs) como finasteride y dutasteride son efectivos solo en pacientes con agrandamiento prostático demostrable (>30 cc en imágenes, PSA >1.5 ng/mL, o agrandamiento palpable en TRD), según la guía de Praxis Medical Insights 5
La evaluación precisa del volumen prostático es importante para determinar opciones de tratamiento para HPB, predecir la respuesta a los 5-ARIs y estimar el riesgo de retención urinaria aguda, según la guía de Praxis Medical Insights 4
Para la medición del tamaño de lesiones prostáticas en la práctica clínica, se recomienda medir dos ejes en un corte axial, preferiblemente en imágenes ponderadas en T2, según la guía de la European Urology 6

The American Urological Association suggests that a prostate volume of >30 cm³ is considered clinically significant enlargement that qualifies patients for 5-alpha reductase inhibitor (5-ARI) therapy, as these medications are only effective in demonstrably enlarged glands 7
A prostate volume of >50-60 cm³ is a relative contraindication for brachytherapy and may require consideration of simple prostatectomy rather than transurethral approaches 8

The ellipsoid formula commonly used with transrectal ultrasound consistently underestimates true prostate volume compared to water displacement measurements, with a standard clinical method for volume estimation 9